MUTO, PIETRO
 Distribuzione geografica
Continente #
NA - Nord America 279
EU - Europa 185
AS - Asia 32
SA - Sud America 1
Totale 497
Nazione #
US - Stati Uniti d'America 279
IE - Irlanda 89
SE - Svezia 73
CN - Cina 30
DE - Germania 9
IT - Italia 7
BE - Belgio 3
PL - Polonia 2
VN - Vietnam 2
BR - Brasile 1
FI - Finlandia 1
FR - Francia 1
Totale 497
Città #
Chandler 118
Dublin 89
Nyköping 48
Ashburn 16
Princeton 14
Medford 13
Des Moines 11
Ann Arbor 10
Beijing 9
Bremen 9
Shenyang 6
Jinan 5
Seattle 5
Wilmington 5
Brussels 3
Castellammare Di Stabia 3
Jacksonville 3
Dong Ket 2
New York 2
Tianjin 2
Warsaw 2
Boardman 1
Catanduva 1
Chengdu 1
Falls Church 1
Hebei 1
Helsinki 1
Houston 1
Jiaxing 1
Messina 1
Mountain View 1
Nanchang 1
Ningbo 1
Norwalk 1
Yicheng 1
Totale 389
Nome #
Axitinib after Sunitinib in metastatic renal cancer: Preliminary results from Italian "Real-World" SAX Study 52
Role of DNA repair machinery and p53 in the testicular germ cell cancer: A review 50
High levels of serum sclerostin and DKK1 in a case of Klippel-Trénaunay syndrome 49
B19Patient (pt) characteristics and treatment patterns in the radium (Ra)-223 REASSURE observational study 46
The neuropathic pain features in Psoriatic Arthritis: a cross-sectional evaluation of prevalence and associated factors 42
Epithelial-mesenchymal transition in prostate cancer: An overview 42
COVID-19 and radiotherapy: potential new strategies for patients management with hypofractionation and telemedicine. Di Franco R, Borzillo V, D'Ippolito E, Scipilliti E, Petito A, Facchini G, Berretta M, Muto P. Eur Rev Med Pharmacol Sci. 2020 Dec;24(23):12480-12489. doi: 10.26355/eurrev_202012_24044. 39
Metabolic syndrome, endocrine disruptors and prostate cancer associations: Biochemical and pathophysiological evidences 36
Rectal/urinary toxicity after hypofractionated vs. Conventional radiotherapy in high risk prostate cancer: Systematic review and meta analysis 34
Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: Systematic review and meta analysis 34
Correction: Metabolic syndrome, endocrine disruptors and prostate cancer associations: Biochemical and pathophysiological evidences [Oncotarget, 8, (2017) (30606-30616)] doi 10.18632/oncotarget.16725 34
Corrigendum: Pazopanib in metastatic renal cancer: A "real-world" experience at national cancer institute "Fondazione G. Pascale" [Front. Pharmacol., 7, 287, (2016)] doi: 10.3389/fphar.2016.00287 30
Pazopanib in metastatic renal cancer: A "real-world" experience at National Cancer Institute "Fondazione G. Pascale" 24
Frequency of Renal Function Parameter Abnormalities in Patients with Psoriatic Arthritis and Rheumatoid Arthritis: Real-World Evidence from Clinical Practice 2
Totale 514
Categoria #
all - tutte 2.660
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.660


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191 0 0 0 0 0 0 0 0 0 0 1 0
2019/202018 0 0 0 0 0 1 0 4 3 4 6 0
2020/202145 1 0 12 1 3 0 1 16 5 3 0 3
2021/202297 1 0 0 1 5 3 5 2 1 5 32 42
2022/2023307 17 30 14 43 22 33 2 15 121 2 7 1
2023/202444 6 9 3 15 2 4 0 5 0 0 0 0
Totale 514